Although ipatasertib inhibits all three isoforms of the AKT enzyme, ipatasertib achieved only one of two co-primary endpoints in Phase III trials in prostate cancer and mTNBC [31, 32]. The gene discussed is AKT1; the disease is prostate carcinoma.